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INTRODUCTION
Epstein– Barr virus (EBV) is a human herpesvirus with a prev-
alence of more than 90% in adults [1]. Acute infection is gen-
erally asymptomatic, but can present clinically as infectious 
mononucleosis (glandular fever) and infection persists latently 
throughout life in B lymphocytes. Intermittent viral reactivation 
drives proliferation of infected cells, which can transform to 
malignant lymphoblasts in the absence of immune surveillance. 
In immunocompetent individuals, EBV- specific T cells control 
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Abstract
Adoptive immunotherapy using Epstein– Barr Virus (EBV)- specific T cells is a poten-
tially curative treatment for patients with EBV- related malignancies where other clini-
cal options have proved ineffective. We describe improved good manufacturing practice 
(GMP)- compliant culture and analysis processes for conventional lymphoblastoid cell line 
(LCL)- driven EBV- specific T cell manufacture, and describe an improved phenotyping 
approach for analysing T cell products. We optimized the current LCL- mediated clinical 
manufacture of EBV- specific T cells to establish an improved process using xenoprotein- 
free GMP- compliant reagents throughout, and compared resulting products with our pre-
vious banked T cell clinical therapy. We assessed effects of changes to LCL:T cell ratio 
in T cell expansion, and developed a robust flow cytometric marker panel covering T cell 
memory, activation, differentiation and intracellular cytokine release to characterize T 
cells more effectively. These data were analysed using a t- stochastic neighbour embed-
ding (t- SNE) algorithm. The optimized GMP- compliant process resulted in reduced cell 
processing time and improved retention and expansion of central memory T cells. Multi- 
parameter flow cytometry determined the optimal protocol for LCL stimulation and 
expansion of T cells and demonstrated that cytokine profiling using interleukin (IL)- 2, 
tumour necrosis factor (TNF)- α and interferon (IFN)- γ was able to determine the differ-
entiation status of T cells throughout culture and in the final product. We show that fully 
GMP- compliant closed- process culture of LCL- mediated EBV- specific T cells is feasi-
ble, and profiling of T cells through cytokine expression gives improved characterization 
of start material, in- process culture conditions and final product. Visualization of the 
complex multi- parameter flow cytometric data can be simplified using t- SNE analysis.
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these reactivations [2]. However, iatrogenic immunosuppres-
sion of patients following haematopoietic stem cell transplant 
(HSCT) or solid organ transplant (SOT) can result in potentially 
fatal EBV- driven post- transplant lymphoproliferative disorder 
(PTLD), where EBV- transformed B cells develop into an ag-
gressive B cell lymphoma [3].
Adoptive immunotherapy using Epstein– Barr Virus 
(EBV)- specific T cell lines has proved to be an effective 
clinical treatment for patients with rituximab- resistant or re-
fractory PTLD [4]. The Scottish National Blood Transfusion 
Service (SNBTS) EBV- specific T cell bank has delivered 
third- party partially human leucocyte antigen (HLA)- 
matched EBV- specific T cells for PTLD patients for more 
than 15 years, allowing a rapid therapeutic intervention fol-
lowing diagnosis, with an initial 52% complete response rate 
in a Phase 2 multi- centre trial [5]. As of December 2020, 
more than 100  SOT and HSCT patients have been treated 
with the more recent second- generation SNBTS T cell bank, 
issued under a Medicines and Healthcare Regulatory Agency 
(MHRA) manufacturing Specials licence for therapeutic 
use. A recent follow- up study of 64 patients with refractory 
disease treated between 2011 and 2017 indicates that over-
all survival at 3 years post- treatment was more than 40% at 
3 years post- infusion, and even higher (62%) in SOT patients, 
depending on the degree of HLA matching available [6]. This 
corresponds well with other clinical studies using adoptive 
therapy with EBV- specific T cells, where overall response 
rates in closely matched donors were 63– 68% (7- 9).
Clinical manufacture of allogeneic EBV- specific T cells for 
therapy requires a generation protocol that conforms to current 
good manufacturing process (cGMP) regulations. Manufacture 
of the current SNBTS second- generation SNBTS T cell bank 
was undertaken using a conventional process for generating 
EBV- specific T cells, using mononuclear cells (MNC) co- 
cultured over 6– 8 weeks with autologous EBV- transformed 
lymphoblastoid cell lines (LCL). The LCL act as antigen- 
presenting cells (APC) to induce proliferation of T cells recog-
nizing EBV viral proteins such as BZLF1 and BMLF1 involved 
in early lytic cycle transactivation, and viral latency proteins 
such as Epstein- Barr nuclear antigen 1 (EBNA1), EBNA2, 
EBNA3, latent membrane protein 1 (LMP1) and LMP2 [10,11]. 
Multiple rounds of stimulation with irradiated autologous LCL 
are required to induce EBV- specific T cell expansion to a suit-
able therapeutic dose [12]. The introduction of rapid expansion 
protocols in development of new T cell therapies [13] indicates 
a need for both robust, rapid methods for EBV- specific T cell 
manufacture and improved analytical methods to assess the 
quality of the material throughout.
Replacement of standard flask culture with gas- permeable 
rapid expansion devices (G- Rex flasks; Wilson Wolf, New 
Brighton, Minnesota, USA) is now established for T cell 
culture, and T cell lines are generally initiated in culture 
with a ratio of 40  MNC:1 LCL for the first stimulation 
round. Subsequent stimulation rounds are generally at a 1 T 
cell:5 LCL ratio in rapid expansion protocols [14], although 
variations in this approach are evident between studies [15– 
18]. As part of this study, we determined the optimal number 
of stimulation rounds and optimized our previous manufacture 
protocol by transfer to European Union (EU) GMP- compliant 
culture reagents (medium and cytokine) and G- Rex flask cul-
ture throughout. We confirmed appropriate T cell:LCL stimu-
lation ratio parameters for culture and in each case utilized an 
extensive multi- parameter flow cytometric analysis approach 
to dissect the composition of the cultures.
The critical quality attributes of the SNBTS therapeutic 
EBV- specific T cells products are stringent and include vi-
ability, T cell lineage and absence of other lymphocytes; for 
this process optimization study we introduced a broader flow 
cytometric analysis panel which allowed characterization of 
the T cell compartment to a much higher level of discrim-
ination. The new panels were able to determine T cell de-
velopment, differentiation and activation status and provide 
markers of efficacy through intracellular cytokine analysis 
for interferon (IFN)- γ, tumour necrosis factor (TNF)- α and 
interleukin (IL)- 2. We utilized these panels to determine the 
efficacy of the modified protocol in comparison with the cur-
rent process, and assess quality from starting mononuclear 
cells through to final T cell product. Visualizing these data 
is complex, and we applied t- stochastic neighbour embed-
ding (t- SNE) algorithms to incorporate multiple parameters 
into a single image, allowing visual comparison of the T cell 
phenotype. This approach provides clear evidence for an im-
proved process for manufacture of virus- specific T cells to a 
standard suitable for clinical use.
MATERIALS AND METHODS
Donor material
Stocks of donor leukapheresis mononuclear cells (MNC)- 
derived EBV- specific T cells and corresponding LCL from 
the SNBTS second- generation bank were supplied from fro-
zen stored stocks. For this bank material, initial leukapheresis 
donations were collected by Spectra Optia apheresis system 
(Terumo BCT, Lakewood, Colorado, USA) and all donations 
were fully consented for research use and were either from 
New Zealand (NZ code, free of variant CJD and suitable for 
therapy); or were from local Scottish donors for research only. 
Autologous EBV- transformed LCL for the second- generation 
bank were generated from NZ donor MNC by infection with 
concentrated EBV- positive supernatant for use as autologous 
antigen presenting cells, as previously described [12]. Briefly, 
supernatant from a live EBV- expressing cell line was added 
to donor MNC and cultured for several rounds until stable 
LCL lines were established. The LCL were frozen in 1 ml 
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aliquots in human serum albumin (HSA) + 10% dimethyl-
sulphoxide (DMSO) until use. Initial work on phenotypical 
development was performed using MNC derived from buffy 
coats from normal blood donors, supplied through SNBTS 
under Sample Governance 14~11.
Generation of EBV- specific T cells in standard 
culture is improved in G- Rex flasks
Standard cultures were generated by rederiving new prod-
ucts from frozen stored leukapheresis samples from six 
donors. These new cultures were grown in standard me-
dium [RPMI + 10% fetal calf serum (FCS) and glutamine] 
in T75  cm2 flasks by mixing thawed apheresis MNC with 
autologous LCL (irradiated at 40  Gy) at an initial ratio of 
40 MNC:1 LCL, and then restimulated with fresh autologous 
LCL for a total of six to eight stimulation rounds. Final T cell 
products (1.0 × 107 cells/ml) were frozen in cryovials from 
each stimulation round and stored for later analysis by flow 
cytometry.
A comparison study set up to assess improvement of 
culture of EBV- specific T cells using closable G- Rex flasks 
(Wilson- Wolf) was carried out using thawed donor leuka-
pheresis material and compared against cultures in con-
ventional open culture flasks. Cells in suspension from 
each donor were split and cultured in either T75  cm2 cul-
ture flasks (1.0  ×  108 MNC  +  2.5  ×  106 LCL, final den-
sity = 1.33 × 106 MNC per cm2) or G- Rex100 cm2 flasks 
(1.0 × 108 MNC + 2.5 × 106 LCL, final density = 1.0 × 106 
MNC per cm2). At day 10, cells in T75  cm2 culture were 
counted, and a second stimulation of autologous irradiated 
LCLs were added at a ratio of 4 T cell:1 LCL and split to 
new T75 cm2 flasks to give a final density of 0.5– 1.0 × 106 
T cells per cm2. For G- Rex cultures at day 10, cells were 
counted and irradiated LCL added at a ratio of 1 T cell:5 
LCL and split to new G- Rex100 cm2 flasks to give a final 
density of 0.1 × 106 T cells per cm2, as indicated in the rapid 
expansion protocol [14]. At day 14, cultures were re- fed with 
IL- 2 at a final concentration of 20  IU/ml. Thereafter, cul-
tures were counted every 3– 4 days and fed/split to new flasks 
as necessary. All cell counts were given as viable cells via 
trypan blue exclusion of dead cells.
Comparison of GMP- compliant reagents and 
stimulation intensity
Small scale studies of EBV T cells cultured in G- Rex flasks 
comparing reagents and stimulation round densities were per-
formed using frozen vials of matched MNC and LCL sup-
plied from the second- generation SNBTS T cell bank. As 
before, on day of initiation LCL were irradiated at 40  Gy 
and mixed with autologous MNC at an initial stimulation 
ratio of 40  MNC:1 LCL. Cells from each donor were di-
vided and cultured in 40  ml culture medium: either RPMI 
with glutamine + FCS (10%) + research- grade IL- 2 (50 IU/
ml) or xeno- free GMP- grade TexMACS (Miltenyi Biotec, 
Auburn, California, USA)  +  GMP- grade IL- 2 (50  IU/ml) 
(both Miltenyi Biotec) and transferred to G- Rex10 cm2 flasks 
(1 × 107 MNC + 2.5 × 105 LCL, final density = 1.0 × 106 
MNC per cm2). Cell counts were taken every 3– 4 days and 
cultures re- fed at these time- points by removing 90% volume 
of media and replacing with fresh media plus IL- 2. At day 10, 
cells were harvested from flasks and recultured at 0.5– 1 × 107 
per G- Rex10 for restimulation with irradiated LCL at 1T 
cell:5  LCL, as per standard G- Rex protocol. Cultures in 
fully GMP reagents were further subdivided into secondary 
stimulation ratios of 1  T cell:5  LCL (standard protocol) or 
1 T cell:1 LCL (reduced- intensity modified protocol). A final 
round of stimulation was performed at day 20, with either 1 T 
cell:5 LCL or 1 T cell:1 LCL for the standard or modified 
protocol, respectively. At day 30, cells were harvested from 
the G- Rex and assessed for yield and viability by trypan blue 
exclusion and tested in the flow cytometric assays below.
Buffy coat MNC isolation
Donor MNC were isolated from healthy donor buffy coats 
by Ficoll- Paque (GE Healthcare, Chicago, Illinois, USA) 
density centrifugation (450 g for 40 min) to set up flow cy-
tometry panels (surface phenotype and intracellular cytokine 
assay). Donor MNC from six buffy coats were also charac-
terized for cytokine expression in relation to T cell memory 
markers (see Intracellular cytokine assay).
Surface phenotyping
Flow cytometric characterization of T cells was carried 
out with surface marker panel: CD45RA- VioBlue, CD8- 
VioGreen, CD62L- fluorescein isothiocyanate (FITC), 
CD3- phycoerythrin (PE) or CD57- PE, CD45RO- peridinin 
chlorophyll (PerCP)- Vio700, CD4- PE- Vio770, CD28- 
APC (all Miltenyi Biotech) and dead cell marker DRAQ7 
(Biolegend, London, UK). Following stimulation by LCL, 
samples were taken weekly to monitor phenotypical changes 
using a modified panel, where CD57- PE (Miltenyi Biotech) 
was used to replace CD3 to monitor terminal differentiation/
senescence.
Briefly, 2 × 106 cells were washed with phosphate- buffered 
saline (PBS) plus 2.5  mM ethylenediamine tetraacetic acid 
(EDTA) (Invitrogen, Carlsbad, California, USA) and 0.5% 
human serum albumen (has) (Alburex) (PEA buffer), blocked 
with 5 μl human Fc receptor block (Miltenyi Biotech), labelled 
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with antibody cocktail at 4°C for 20 min, washed and DRAQ7 
added prior to analysis. Approximately 100 000 live events 
were acquired using a MACSQuant10 (Miltenyi Biotech) or 
BD Fortessa LSR (Becton Dickinson, San Jose, California, 
USA) flow cytometer with data analysis using FlowJo version 
10 software (Tree Star, Inc., Ashland, Oregon, USA). All flow 
cytometric analyses were based on a manual gating strategy 
as described in Figure 1a, with lymphocyte population identi-
fied by scatter, then doublets and dead cells excluded (singlet 
gated/DRAQ7− cells). Data were collected as percentages of 
gated populations as mean fluorescence intensity (MFI), or as 
a corrected MFI (target MFI– isotype MFI).
Intracellular cytokine assay
Intracellular staining to characterize T cell populations based 
on cytokine profile was developed. This approach used phor-
bol myristate acetate (PMA)/ionomycin stimulation to drive 
maximal cytokine response in the T cells. Cells were stimu-
lated with 2 μl/ml cell activation cocktail (PMA/ionomycin; 
Biolegend) for 2  h, then brefeldin A (5  μg/ml, Biolegend) 
was added for a further 3 h. Non- activated cells treated with 
brefeldin A were used as negative controls. Cells were har-
vested, washed twice in PEA and surface markers labelled 
with CD8- VioGreen, CCR7- FITC, CD57- PE and CD45RO- 
PerCP- Vio700 (Miltenyi Biotech) as before, washed in PBS 
plus 2.5  mM EDTA (PE buffer) and stained with 1  μl/ml 
Fixable Viability Dye eFluor™ 780 (eBioscience, Cheshire, 
UK) for 30 min at 4°C. Cells were washed again in PE, then 
fixed and permeabilized as per the manufacturer’s instruc-
tions (BD Biosciences) and labelled with IFN- γ- eFluor450 
(eBioscience), TNF- α- PE- Vio770 and IL- 2- APC (both 
Miltenyi Biotech) for 30 min. Cells were washed again and 
resuspended in PE and up to 100 000 live events recorded 
on MACSQuant10/BD Fortessa LSR. Further assessment of 
virus- specific responses in the T cells was performed in a 
representative GMP isolate, using stimulation with an EBV- 
specific peptide pool (EBV- Peptivator; Miltenyi Biotech) 
with PMA/ionomycin as a positive control. The sample was 
also labelled for markers of cytotoxic function (perforin- PE 
and CD107a- APC).
Flow cytometry gating strategy and 
t- SNE analysis
Phenotypes were defined using a combination of expression 
of surface markers with intracellular cytokine expression 
after stimulation with PMA/ionomycin (versus relevant neg-
ative and isotype controls). Representative flow cytometric 
data from second- generation bank EBV- specific T cell final 
product with initial gating of lymphocytes/singlets/live cells 
is outlined in Supporting information, Figure S1. Lineage 
was identified through CD4 versus CD8 labelling and dif-
ferentiation status through surface expression of CD45RO/
CD45RA and CD62L or CCR7 (Supporting information, 
Figure S1b). Analysis of cytokine expression (Supporting in-
formation, Figure S1c) was based on gating CD8+/CD45RO+ 
viable lymphocytes, dividing into IL- 2low and IL- 2high popu-
lations, and then quadrant gating each IL- 2 subpopulation for 
IFN- γ and TNF- α co- expression. A contrasting profile of T 
cell cytokine expression of a heterogeneous pan T cell com-
partment in MNC freshly isolated from buffy coat donors is 
shown in Supporting information, Figure S2.
t- SNE analysis was applied to multi- parameter flow cy-
tometric data. Briefly, analyses were gated on lymphocyte/
singlet/live as above using FlowJo, and reduced to a repre-
sentative 10  000 events using Downsample (both Becton 
Dickinson). The t- SNE maps were generated using the 
FlowJo plugin for 800 iterations at perplexity 20. Events 
from each Downsample population were spatially correlated 
in terms of likeness for all fluorescent parameters. Manual 
gating overlays were used to subdivide CD8+ and CD4+ cells 
into T cell memory populations based on surface marker 
expression:naive (CCR7+CD45RO−), T central memory 
(TCM) (CCR7+CD45RO+), T effector memory (TEM) 
(CCR7−CD45RO+) and terminally differentiated effectors 
expressing CD45RA TEMRA (CCR7−CD45RO−).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
version 7.01 software (GraphPad Software, San Diego, 
California, USA). Comparisons between groups were made 
on the basis of the difference in mean percentage of cells 
positive for surface marker expression for phenotypical anal-
yses, the mean fluorescence intensity corrected to negative 
control (cMFI) of anti- cytokine antibodies for intracellular 
cytokine production analyses and the difference in mean cell 
number/yield for cell expansion analyses. Significance was 
calculated using unpaired two- tailed Student’s t- tests with 
Holm– Sidak correction for multiple tests, where a p value 
of < 0.05 was considered significant.
RESULTS
Determining optimal stimulation round for 
effective EBV- specific T cell manufacture
Third- party EBV- specific T cell banks based on LCL stim-
ulation involve leukapheresis- derived MNC co- cultured 
with irradiated autologous LCL through several rounds to 
generate a relatively homogeneous virus- specific T cell 
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product. We hypothesized that multiple rounds of LCL- 
mediated antigen presentation could potentially lead to 
exhaustion of virus- specific T cells. To determine this, we 
rederived exemplars from our second- generation EBV- 
specific T cell bank leukapheresis and LCL stocks and 
analysed cells by flow cytometry at 7– 9  days following 
each successive stimulation round to characterize pheno-
typical development. Changes in CD4/CD8 ratio were seen 
through each round of stimulation (Figure 1a), indicating 
that the CD4 population forms fewer than 1% of the total 
T cells from stimulation round (SR) four onwards. The 
corresponding IFN- γ/TNF- α expression in the CD8 TCM, 
TEM and differentiated effector (TEMRA) compartment 
shows that the majority of cells (86%) co- express IFN- γ 
and TNF- α in response to PMA/ionomycin stimulation 
(Figure 1a, lower panel). From SR2 onwards this increases 
to more than 97% IFN- γ+/TNF- α+, indicating that the CD8 
compartment rapidly progresses to functional cytotoxic 
T cells. However, the percentage of cytokine expression 
stabilizes after SR3, indicating no significant benefit to 
functional capacity with multiple rounds of LCL stimula-
tion. This was quantified in six different EBV- specific T 
cell lines [data are represented as mean  ±  standard error 
of the mean (SEM)], and confirmed that outgrowth of the 
F I G U R E  1  Sequential lymphoblastoid cell line (LCL) stimulation affects Epstein– Barr virus (EBV)- specific T cell development. Samples 
were taken 7– 9 days after each stimulation round (SR) from six different donor EBV- specific T cell lines. (a) The T cell ratio shows rapid 
transformation to a highly enriched CD8+ T cell product by stimulation round (SR) 3– 4, with most gated CD8+CD45RO+ cells co- expressing 
interferon (IFN)- γ and tumour necrosis factor (TNF)- α by stimulation round 2, peaking at SR3. These are maximal cytokine responses driven by 
phorbol myristate acetate (PMA)/ionomycin. Flow plots are from representative EBV- specific T cell line NZ873. The mean percentage of (b) T 
cell subpopulations (CD8+, CD4+, CD8−CD4−) and (c) CD45RO+, CD45RA+ and CD57+ in CD8 cells at each SR (n = 6) is shown, demonstrating 
consistent development of CD8+ enriched products and consistent differentiation status by SR3. (d) The mean control mean fluorescence intensity 
(cMFI) of IFN- γ, TNF- α and IL- 2 expression in CD8+CD45RO+ cells reaches a plateau by SR3 then decreases, indicating that peak functionality 
occurs within three stimulation rounds. Data are represented as mean ± standard error of the mean (SEM)
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CD8 population was consistent (Figure 1b). The mean per-
centage of CD8+/CD45RO+ cells peaks at SR3 (Figure 
1c) then starts to decrease, indicating a trend towards 
down- regulation of CD45RO with continued stimulations. 
Expression of the activation/senescence marker CD57 also 
shows a marginal increase throughout subsequent stimu-
lation rounds. While the mean percentage of TNF- α/IFN- 
γ- expressing CD8+ T cells does not vary significantly 
throughout, it is clear that the mean fluorescence intensity 
corrected to negative control (cMFI) of TNF- α and IFN- γ 
peaks at SR3 or 4 and then starts to decrease (Figure 1d), 
indicating that extending stimulation beyond four rounds 
potentially compromises functional cytokine levels. The 
results from Figure 1 suggest that EBV- specific T cell 
cultures reach peak product quality by SR3/4, after which 
functional parameters decline.
GMP- translatable culture vessels improve 
manufacturing outcomes
The SNBTS second- generation EBV- specific T cell bank was 
manufactured in standard culture flasks, and we determined 
whether transfer to more GMP- compliant G- Rex culture 
flasks would affect T cell phenotype or functional markers. 
Apheresis material from healthy EBV seropositive donors 
(n = 6) were used to establish fresh EBV- specific T cell cul-
tures, and each donor culture was split to directly compare 
culture in closable G- Rex flasks (G- Rex100) versus standard 
tissue culture flasks (Corning, London, UK) through an op-
timized three- round stimulation process. The G- Rex flasks 
used had a standard research cap, but are identical to GMP- 
compliant flasks which have a closed- process cap, so can be 
considered GMP- translatable. At day 30 (9  days after the 
third LCL stimulation), cells were harvested from both cul-
ture vessels and analysed by surface and intracellular cytokine 
phenotyping. The mean percentage of CD8+ T cells was sig-
nificantly higher (p = 0.012) in G- Rex flasks than in stand-
ard flasks (90.2 ± 3.49% versus 78.4 ± 2.11%, respectively, 
Figure 2a). However, T cell surface marker phenotypes did 
not differ significantly between culture flasks (Figure  2b). 
Intracellular cytokine analysis after PMA/ionomycin stim-
ulation demonstrated that there was no significant differ-
ence in either quantity of cytokine expression (measured by 
cMFI, Figure 2c) or cytokine co- expression subpopulations 
in CD8+ T cells between flasks (Figure 2d). These results 
demonstrate that using manufacturing- scale G- Rex culture 
flasks not only allows increased cell expansion [14], but also 
develops a more consistent T cell phenotype in a shorter pe-
riod of time than culture in conventional Corning flasks. This 
process is then readily transferable to G- Rex closed- system 
flasks to allow a fully closed manufacturing process via use 
of the GatheRex cell harvester (Wilson Wolf).
Comparability of EBV- specific T cells 
generated using GMP- compliant reagents
The SNBTS second- generation EBV- specific T cell bank 
utilized some non- GMP standard reagents, including FCS 
for LCL culture. We assessed whether EBV- specific T cell 
products cultured in GMP- compliant reagents including xen-
oprotein- and serum- free culture medium throughout would 
generate comparable T cell products. Culture was performed 
in G- Rex100 flasks using the optimized three- round stimu-
lation protocol and assessment of T cell characteristics was 
carried out as before. In final product, EBV- specific T cells 
grown in GMP- compliant reagents throughout, the surface 
phenotype (Figure 3a,b) was substantially similar to those 
grown in research- grade reagents. A key improvement 
was a significantly higher percentage of TCM (CD62L+/
CD45RO+) cells in the GMP- compliant conditions (n = 4).
There were no significant differences between the groups 
for cytokine co- expressing populations (Figure 3d), although 
a trend towards increased cytokine levels was observed in 
GMP- compliant cultures (Figure 3c). These data demonstrate 
that GMP- compliant reagents used with G- Rex culture flasks 
results in EBV- specific T cell cultures that are comparable 
to current bank material, and have improved retention of the 
TCM compartment.
Optimization of T cell: LCL ratio for EBV 
antigen- driven stimulation
Conventionally, ex- vivo expansion of EBV- specific T cells 
has been performed using a ratio of 40 MNC:1 LCL for the in-
itial stimulation, and subsequent stimulation rounds at a ratio 
of 1 T cell:5 LCL in G- Rex rapid expansion protocol, which 
could potentially drive anergy, senescence or activation- 
induced cell death (AICD). We determined whether modu-
lation of the stimulation ratio conferred benefits in terms of 
functional subpopulation profile.
T cell cultures from four EBV seropositive donors were 
initiated using an initial concentration of 40  MNC:1  LCL 
as per standard protocol, then at SR2 or SR3 cultures were 
split and co- cultured at standard (1 T cell:5 LCL) or at lower 
intensity (1  T cell:1  LCL). At day 30 (the end of SR3), a 
direct comparison of each stimulation ratio was assessed. 
Mean harvest cell counts indicated a 28.1 ± 13.63- fold ex-
pansion for 1 T cell:5 LCL cultures and 21.68 ± 9.24- fold 
expansion for 1 T cell:1 LCL cultures (Figure 4a). Samples 
taken at day 30 were comparable for surface marker analysis, 
with ~90% CD8+ cells and equivalent levels of each surface 
marker subset (Figure 4b). While the percentage of T cells 
with co- expression of IFN- γ/TNF- α was equivalent between 
the two groups (Figure 4d), the cMFI of IFN- γ (Figure 4c) 
was significantly higher (p  =  0.00218) in 1  T cell:1  LCL 
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cultures (mean  =  162.5  ±  16.03) than in 1  T cell:5  LCL 
cultures (mean  =  77.65  ±  25.50). Similarly, TNF- α cMFI 
was significantly increased (p = 0.0202) in 1 T cell:1 LCL 
cultures (mean  =  112.18  ±  18.56) than in 1  T cell:5  LCL 
cultures (mean  =  53.69  ±  12.2). The increased cytokine 
cMFI indicates co- culture with a lower intensity LCL stim-
ulation result in EBV- specific T cells with an enhanced ca-
pacity for functional cytokine secretion. These data clearly 
demonstrate the robustness of the current LCL- based method 
for EBV- specific T cell stimulation and expansion, as most 
parameters are unaffected by the modification of LCL ratios. 
However, the finding that reducing LCL dose corresponds 
with increased secretion of IFN- γ and TNF- α, which may en-
hance effector functions of these cells in vivo, suggests that 
the EBV- specific T cell culture product can be optimized. 
We have therefore demonstrated that our optimized culture 
F I G U R E  2  Comparison of culture vessel for T cell products. Co- cultures of apheresis mononuclear cells (MNC) and autologous 
lymphoblastoid cell lines (LCLs) were set up (n = 6 donors) to compare culture in Corning flasks versus G- Rex100 flasks through an optimized 
three- stimulation- round protocol. Harvested samples were compared for phenotypical and functional profiles, as before. (a) Cultures from G- Rex 
flasks had a significantly higher percentage of CD8+ cells than standard flask- grown lines (p < 0.05). (b) CD8+ cell phenotype was consistent 
between both culture methods for all markers analysed. Intracellular analysis of the gated CD8+CD45RO+ cells showed no difference between 
standard flask and G- Rex cultured T cells for (c) expression of cytokines by control mean fluorescence intensity (cMFI) or (d) relative frequencies 
of differentiated subpopulations by cytokine expression. Data are represented as mean ± standard error of the mean (SEM)
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approach provides a significant improvement in retention 
of TCM cells with increased cytokine expression. In addi-
tion, we were able to demonstrate in a representative GMP- 
compliant product that there was both clear virus- specific 
reactivity in response to a pooled selection of EBV peptides 
(EBV Peptivator; Miltenyi Biotech) and expression of cyto-
toxic functional markers (perforin/CD107a) in the final T cell 
product (Supporting information, Figure S3). The expanded 
phenotyping approach allows for a better characterization 
of start material and final products, and we assessed how to 
F I G U R E  3  Samples taken at day 30 harvest from G- Rex10 flasks (stimulation rounds 3 + 9 days) analysed as before. (a) Direct comparison 
of representative line ladinin 1 (LAD1) cultured using good manufacturing practice (GMP)- compliant reagents and standard culture reagents 
demonstrated both T cell cultures had comparable expression of most markers, but reduced CD57 expression in the GMP- compliant process. 
(b) Analysis of mean surface marker expression showed a significantly higher percentage of CD62L+CD45RO+ central memory T cells in 
GMP- compliant culture (n = 4) compared to standard (n = 4, p = 0.002). Intracellular staining showed no significant difference in (c) cytokine 
expression between the two groups or (d) relative frequency of differentiated T cell subpopulations by cytokine expression. Data are represented as 
mean ± standard error of the mean (SEM)
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analyse the data from this multi- parameter flow cytometric 
approach more effectively.
Comparing T cell memory status using surface 
marker and cytokine profiles
The flow cytometric characterization of EBV- specific T 
cells in the current second- generation SNBTS bank was 
restricted to a small panel of essential lineage markers: 
CD8, CD4, CD19 and CD56 plus 7- aminoactinomycin D 
(7- AAD) for viability. Manufacturing release criteria were 
confined to the presence of <2% CD19 B cells (as a marker 
of LCL contamination) and >10% specific lysis against 
autologous LCLs by cytotoxicity assay. In this study we 
extended this analysis to characterize T cell products on 
the basis of lineage, memory and differentiation status, 
and correlate this with cytokine profile to improve the 
F I G U R E  4  Modifying lymphoblastoid cell line (LCL) [cytotoxic T lymphocyte (CTL):LCL] ratio improves cytokine expression. T cell 
cultures from four donors were split to directly compare stimulation rounds (SR) 2 and 3 of co- culture at standard (1 T cell:5 LCL) or reduced 
intensity (1 T cell:1 LCL). (a) Fold expansion of viable lymphocytes between SR2 initiation (day 10) and end of SR3 (day 30) was calculated 
from viable cell count. (b) Surface phenotype of final products remain comparable between the two groups for all markers analysed. (c) Reduced 
intensity culture had a significantly higher control mean fluorescence intensity (cMFI) of interferon (IFN)- γ (p = 0.00218) and tumour necrosis 
factor (TNF)- α (p = 0.0202) in response to phorbol myristate acetate (PMA)/ionomycin stimulation (corrected to negative controls) compared to 
the standard ratio cultures. (d) In CD8+CD45RO+ T cells, there was an even distribution of central memory and effector memory compartments 
with reduced intensity conditioning, and a skew towards effector memory in standard process. Data are represented as mean ± standard error of the 
mean (SEM)
   | 77CYTOKINE ANALYSIS FOR EBV- T CELL THERAPY
assessment of quality and potential functionality of T cell 
material used for clinical therapy. This was used to assess 
the outcomes from optimization of the LCL- based manu-
facturing method.
Optimized phenotyping and t- SNE analysis for 
T cell products
Conventionally, T cell memory subtypes are identified 
through co- expression of homing receptors such as CD62L 
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and CCR7 with leucocyte common antigen (CD45) isoforms 
RO and RA, but these memory types can also be classified by 
cytokine co- expression (Supporting information, Figure S4). 
We characterized T cells from start material through to final 
product for memory/differentiation status using a combined 
surface marker/intracellular cytokine panel, and used t- SNE 
analysis to simplify multi- parameter phenotyping.
The t- SNE dimensionality reduction identified a clear se-
quential spatial correlation in both the CD4 and CD8 differ-
entiation from naive (CCR7+/CD45RO−) to TCM (CCR7+/
CD45RO+) to TEM (CCR7−/CD45RO+) to TEMRA (CCR7−/
CD45RO−) stages. Furthermore, fluorescent intensity heat 
maps applied over this same t- SNE plot (Figure 5b) indicated 
the highest intensity of IFN- γ in the CD8+ TEM region; the 
highest intensity of TNF- α in the CD8+ TEM and CD4+ TEM 
regions; and the highest intensity of IL- 2 in the CD8+ TCM 
and CD4+ TCM/TEM compartments, confirming the correla-
tion of differentiation status with cytokine profile.
As CD8+ T cells form the principal component of the final 
cell therapy product, the CD8+ naive, TCM, TEM and TEMRA 
populations were then sequentially analysed by expression 
of cytokines IFN- γ, TNF- α and IL- 2. The mean percentage 
of each cytokine subpopulation from six buffy coat- derived 
MNC donors stimulated with PMA/ionomycin is expressed 
in pie chart format in Figure 5c. The majority of CD8+ naive 
T cells are cytokine- null, with the remaining 26.2% mainly 
comprising IL- 2- or TNF- α- expressing cells. The CD8+ TCM 
cells predominantly express all cytokines (IFN- γ+/TNF- α+/IL- 
2+), although there is also a distinct TNF- α+/IL- 2+ population 
(27%) within this subset which represents early central mem-
ory development. Within the CD8 TEM compartment, there 
is developmental transition from central memory (retention of 
IFN- γ+/TNF- α+/IL- 2+) into more effector- like IFN- γ+/TNF- 
α+ co- expressing cells, which form almost 50% of the TEM 
subpopulation. The CD8 TEMRA population shows further 
transition, with IFN- γ+/TNF- α+- or IFN- γ+- only T cells form-
ing the principal population, with a small residual population 
retaining some TCM (IFN- γ+/TNF- α+/IL- 2+) characteristics. 
There is also an increased presence (17%) of cytokine- null T 
cells, suggesting that some cells may have become anergic, 
with no functional secretory response. Importantly, these data 
demonstrate the limitations of trying to discern T cell memory 
phenotype purely through surface marker expression alone. 
For example, even within the conventionally defined naive 
cells (CCR7+/CD45RO+), which are typically described as cy-
tokine null, there are evident small subpopulations within that 
secrete cytokines.
The use of t- SNE dimensionality reduction generates a 
single- image analysis of complex multi- parameter flow cy-
tometric data which can be utilized to gain a clear represen-
tation of the outgrowth of a small discrete T cell population 
into the final product. Using the data from Figure 1 for se-
quential stimulation rounds, the t- SNE plots demonstrate a 
clear pattern of quality and composition changes from the 
start material to the final T cell product (Figure 5d).
DISCUSSION
The SNBTS currently provides allogeneic third- party 
EBV- specific T cells for patients with relapsed/refractory 
post- transplant lymphoproliferative disease (PTLD). As of 
November 2020, more than 100 patients with relapsed or re-
fractory PTLD have been treated from the current bank under a 
Specials license, with a mean overall survival rate of over 40% 
at 3  years post- treatment. Patients in this cohort with PTLD 
arising after solid organ transplant had better outcomes, with 
survival of more than 60% at 3 years post- treatment, and with 
minimal adoptive cell therapy- related side effects [5].
The current bank of EBV- specific T cells was manufac-
tured from 2007 to 2014, and changes to GMP standards 
since this period have driven a requirement to optimize and 
refine the current manufacturing processes [19]. More re-
cent methods for generation utilize cytokine release assays 
to capture virus- specific T cells, although this requires a 
different expansion process. LCL- based stimulation and ex-
pansion protocols are still in regular use for development of 
anti- cancer therapies [20– 22], and therefore there is a need to 
identify optimal methods for production and analysis.
In this study we demonstrated that optimization of the 
standard autologous LCL- based method of EBV- specific T 
cell manufacturing to a fully GMP- compliant closed- system 
F I G U R E  5  Analytical phenotyping of T cell memory (TCM) subpopulations. Differentiation profiles of the T cell compartment were identified 
by combination of surface marker and intracellular cytokine detection. Donor mononuclear cells (MNCs) freshly isolated from buffy coats were 
stimulated to induce cytokine expression, and CD8+ and CD4+ populations were gated into T cell memory subsets dependent upon surface 
marker expression:naive (CCR7+CD45RO−), TCM (CCR7
+CD45RO+), TEM (CCR7
−CD45RO+) and terminally differentiated effectors expressing 
CD45RA (TEMRA) (CCR7
−CD45RO−). Stochastic neighbour- embedding (t- SNE) analysis was used to cluster cellular subpopulations. (a) Manual 
gating overlays of an exemplar demonstrate the distribution of CD8 and CD4 memory subtypes in the total lymphocyte population. This same plot 
was also analysed for individual cytokines by fluorescence intensity. (b) Each subtype was then quantified for expression of single or multiple 
cytokines, as outlined in the gating strategy. The relative frequency of cytokine subpopulations from representative MNC demonstrates changes in 
cytokine expression throughout T cell differentiation (mean of n = 6). (c) This analysis was applied to our Epstein– Barr virus (EBV)- specific T cell 
product using exemplar line NZ873 at optimized culture conditions above [in good manufacturing practice (GMP) reagents within G- Rex flasks 
at 1 T cell:1 stimulation round lymphoblastoid cell line (SRL CL) ratio], where there is clear outgrowth of CD8+ cells (blue) expressing cytokines 
from initial MNC starting material throughout the stimulation rounds
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process is feasible without compromise in quality of final cell 
product. The modifications to protocol, reagents and culture 
process were assessed principally using flow cytometry, which 
provides a rapid and quantitative method for analysis. Robust, 
validated flow cytometric assays are a cornerstone of effective 
reproducible cell therapy manufacture [23]. The use of flow 
cytometric analysis and functional profiling of EBV- specific T 
cells through cytokine expression in this study resulted in im-
proved characterization of both start material and final product 
and effective assessment of in- process culture optima, which 
has been used for analysis of other T cell therapeutics, includ-
ing a SARS- CoV- 2- specific T cell product for COVID- 19 
treatment [24]. The improvements in process and final T cell 
product have been demonstrated within this study, but as this 
new product has not been subsequently tested in patients we 
are not able to correlate these improvements with clinical out-
come. Further work is in progress to address this issue.
Intracellular cytokine staining for IL- 2, TNF- α and 
IFN- γ provides a reliable method for discriminating the 
differentiation state of T cells [25,26]. The combination of 
multi- parameter cytokine secretion- based phenotyping with 
t- SNE analysis forms a powerful tool for dissecting subpop-
ulations within the CD8+ cytotoxic T cell compartment, and 
was used as the basis for analysis of improvements and re-
finements in the manufacturing of the current SNBTS EBV- 
specific T cell therapy used for treatment of PTLD [19].
Using the combined surface marker and intracellular cy-
tokine flow cytometric phenotyping approach we were able 
to identify that multiple rounds of LCL stimulation were un-
necessary, and that extending stimulation may increase the 
level of anergy or loss of function in the T cells, as identified 
by a loss of absolute IFN- γ secretion and increased expres-
sion of CD57, a marker of terminal effector differentiation 
[27]. However, the reduction in stimulation round to maxi-
mize functional responses needs to be balanced with the re-
quirement for high yields of cells for treatment of multiple 
patients from a single manufacturing run.
Adoptive T cell therapy relies on large- scale expansion of 
functional T cells to manufacture clinically relevant numbers 
for patient infusion, conventionally through the use of stan-
dard culture flasks or gas- permeable bags. The introduction 
of large- volume, high gas exchange culture vessels (G- Rex 
flask; Wilson Wolf) has significantly improved the rate and 
extent of T cell expansion capacity [28]. The G- Rex flasks are 
GMP- compliant and are scalable up to 1- litre flasks, which 
are qualified as a Food and Drug Administration (FDA) Class 
1 medical device allowing full closed- process manufacture. 
This closed- process manufacture involves suitable sealed 
flasks, transfer bags, heat- sealed tubing and the GatheRex 
cell harvester pump (Wilson Wolf) to ensure sterility in the 
clinical product. We identified that cell yields could also be 
improved using G- Rex flasks for culture with no significant 
changes in phenotype. A minor change in T cell composition 
was identified in the G- Rex cultures, with increase in the per-
centage of CD8 cells. This consistency of final product phe-
notype was also retained when all reagents were converted 
to fully GMP- compliant standards. GMP- compliant medium 
and cytokines with no exogenous xenoproteins ensured that 
the modified process complied with current regulatory re-
quirements. T cells generated with GMP compliant reagents 
and flasks suitable for closed- process culture had a signifi-
cant increase in retention of the TCM compartment. This has 
advantages for persistence of the cell therapy once adminis-
tered to a patient [29,30].
A principal concern with the current LCL- based stimula-
tion process is that high LCL (and therefore viral antigen load) 
ratio to T cells combined with multiple rounds could drive 
T cell exhaustion [31,32] and the reduced T cell:LCL ratio 
process outlined here quantified whether this resulted in func-
tional differences. The LCL process appears robust, as reduced 
intensity stimulation over three rounds did not significantly 
affect the phenotype of the T cells at end- point, although the 
reduced ratio exhibited a significantly enhanced CD8+ cell se-
cretion of IFN- γ and TNF- α. The anticipated antigen- driven 
exhaustion might be seen at higher LCL to T cell ratios, but 
further work is required to elucidate this. The only other mod-
ulation of culture processes that was not undertaken was to 
replace or supplement IL- 2 with other gamma- chain- specific 
T cell growth factors. However, other studies have concluded 
that changing the cytokine- mediated expansion method from 
IL- 2 to other cytokines such as IL- 7, IL- 15 or IL- 21 has no 
significant effect on the overall phenotype or function of T 
cells for therapy [33]. The increased production of IFN- γ and 
TNF- α in response to stimulation in the reduced- intensity 
LCL stimulation may suggest that products made using this 
protocol could have increased effector functions against viral- 
infected cells following patient engraftment.
A key feature of this work was to identify a robust panel 
of surface and intracellular markers which could effectively 
classify the T cell differentiation status and development 
from initial material through to final product. Our approach 
supplies clear data for this, and demonstrates the utility of 
this approach for T cell therapies [24]. In addition, the use 
of t- SNE dimensionality reduction was very effective at con-
densing multiple parameters into a single image which could 
be used to delineate the differentiation stages of the T cells 
from naive to effector using cytokine expression to enhance 
standard surface lineage marker data. In addition, the single 
t- SNE image approach is a useful graphical representation 
to identify the status of the material at any stage of manu-
facture. The images are both illustrative and quantitative and 
could, therefore, be used as part of a standardized product 
release process. The data showing the transition of the rele-
vant small T cell component in the starting mixed leucocyte 
material to its expansion to the final product gives a possible 
multi- parameter analysis for quality control as part of a batch 
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manufacturing record. This cytometric phenotype and anal-
ysis approach is sufficiently adaptable and inclusive that it 
would be suitable for phenotypical and functional assay of 
other cellular therapies, including virus- specific and geneti-
cally modified T cell products [24,34– 37].
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